These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26708937)

  • 1. Cancer immune contexture and immunotherapy.
    Becht E; Giraldo NA; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
    Curr Opin Immunol; 2016 Apr; 39():7-13. PubMed ID: 26708937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
    Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
    Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.
    Bremnes RM; Busund LT; Kilvær TL; Andersen S; Richardsen E; Paulsen EE; Hald S; Khanehkenari MR; Cooper WA; Kao SC; Dønnem T
    J Thorac Oncol; 2016 Jun; 11(6):789-800. PubMed ID: 26845192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune contexture in cancer prognosis and treatment.
    Fridman WH; Zitvogel L; Sautès-Fridman C; Kroemer G
    Nat Rev Clin Oncol; 2017 Dec; 14(12):717-734. PubMed ID: 28741618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune contexture of primary and metastatic human tumours.
    Giraldo NA; Becht E; Remark R; Damotte D; Sautès-Fridman C; Fridman WH
    Curr Opin Immunol; 2014 Apr; 27():8-15. PubMed ID: 24487185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer.
    Wu T; Wu X; Wang HY; Chen L
    Cancer Commun (Lond); 2019 Apr; 39(1):21. PubMed ID: 30999966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting regulatory T cells in tumors.
    Liu C; Workman CJ; Vignali DA
    FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor immunosurveillance in human cancers.
    Mlecnik B; Bindea G; Pagès F; Galon J
    Cancer Metastasis Rev; 2011 Mar; 30(1):5-12. PubMed ID: 21249426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
    Galon J; Angell HK; Bedognetti D; Marincola FM
    Immunity; 2013 Jul; 39(1):11-26. PubMed ID: 23890060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classifying Cancers Based on T-cell Infiltration and PD-L1.
    Teng MW; Ngiow SF; Ribas A; Smyth MJ
    Cancer Res; 2015 Jun; 75(11):2139-45. PubMed ID: 25977340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating RNA expression and visual features for immune infiltrate prediction.
    Reiman D; Sha L; Ho I; Tan T; Lau D; Khan AA
    Pac Symp Biocomput; 2019; 24():284-295. PubMed ID: 30864330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cancer-Specific Qualitative Method for Estimating the Proportion of Tumor-Infiltrating Immune Cells.
    Xiao H; Zhang J; Wang K; Song K; Zheng H; Yang J; Li K; Yuan R; Zhao W; Hui Y
    Front Immunol; 2021; 12():672031. PubMed ID: 34054849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.
    Zhang Y; Chen L
    JAMA Oncol; 2016 Nov; 2(11):1403-1404. PubMed ID: 27490017
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolution of Metastases in Space and Time under Immune Selection.
    Angelova M; Mlecnik B; Vasaturo A; Bindea G; Fredriksen T; Lafontaine L; Buttard B; Morgand E; Bruni D; Jouret-Mourin A; Hubert C; Kartheuser A; Humblet Y; Ceccarelli M; Syed N; Marincola FM; Bedognetti D; Van den Eynde M; Galon J
    Cell; 2018 Oct; 175(3):751-765.e16. PubMed ID: 30318143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium channels of T lymphocytes take center stage in the fight against cancer.
    Conforti L
    J Immunother Cancer; 2017; 5():2. PubMed ID: 28105369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel avenues in immunotherapies for colorectal cancer.
    Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune microenvironment: a major player in human cancers.
    Fridman WH; Remark R; Goc J; Giraldo NA; Becht E; Hammond SA; Damotte D; Dieu-Nosjean MC; Sautès-Fridman C
    Int Arch Allergy Immunol; 2014; 164(1):13-26. PubMed ID: 24852691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells in cancer; can they be controlled?
    Adeegbe DO; Nishikawa H
    Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming tumor-mediated immunosuppression.
    Schlößer HA; Theurich S; Shimabukuro-Vornhagen A; Holtick U; Stippel DL; von Bergwelt-Baildon M
    Immunotherapy; 2014; 6(9):973-88. PubMed ID: 25341119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers.
    Chabab G; Boissière-Michot F; Mollevi C; Ramos J; Lopez-Crapez E; Colombo PE; Jacot W; Bonnefoy N; Lafont V
    Cells; 2020 Jun; 9(6):. PubMed ID: 32599843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.